PD-1/PD-L1 Inhibitors May Improve Survival in NPC
Meta-analysis suggests survival and response benefits alongside notable toxicity in recurrent or metastatic disease
By
Andrea Surnit
April 22, 2026
Clinical Scorecard: PD-1/PD-L1 Inhibitors May Improve Survival in NPC
At a Glance
Category Detail
Condition Recurrent or metastatic nasopharyngeal carcinoma (NPC) Key Mechanisms Inhibition of programmed cell death protein 1 and programmed cell death ligand 1 pathways Target Population Patients with recurrent or metastatic NPC Care Setting Oncology clinics and hospitals
Key Highlights
Median progression-free survival (PFS) of 4.21 months Median overall survival (OS) of 16.27 months 1-year PFS rate of 43% and OS rate of 80% Pooled objective response rate (ORR) of 45% and disease control rate (DCR) of 65% Adverse events occurred in 90% of patients, with 34% experiencing grade 3 or higher events Guideline-Based Recommendations
Diagnosis
Evaluate patients with recurrent or metastatic NPC for PD-1/PD-L1 inhibitor therapy Management
Consider PD-1/PD-L1 inhibitors as a treatment option for eligible patients Monitoring & Follow-up
Monitor for adverse events and treatment response during therapy Risks
High incidence of adverse events, including severe reactions in a subset of patients Patient & Prescribing Data
Patients with recurrent or metastatic nasopharyngeal carcinoma
Recent studies suggest improved ORR and DCR, potentially due to better patient selection and treatment strategies
Clinical Best Practices
Utilize systematic reviews and meta-analyses to inform treatment decisions Consider individual patient characteristics when selecting treatment regimens Stay updated on emerging evidence to refine treatment approaches References
